The global narcolepsy therapeutics market size is calculated at USD 3.83 billion in 2024, grew to USD 4.12 billion in 2025, and is predicted to hit around USD 8.04 billion by 2034, poised to grow at a CAGR of 7.7% between 2024 and 2034. The North America narcolepsy therapeutics market size accounted for USD 1.46 billion in 2024 and is anticipated to grow at the fastest CAGR of 7.82% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Narcolepsy Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Narcolepsy Therapeutics Market, by Treatment, 2024-2034
8.1.1. Narcolepsy With Cataplexy
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Narcolepsy Without Cataplexy
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Secondary Narcolepsy
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. Narcolepsy Therapeutics Market, by Product, 2024-2034
9.1.1. Central Nervous System Stimulants
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Sodium Oxybate
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Selective Serotonin Reuptake Inhibitor
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Tricyclic Antidepressants
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.1.2. Market Revenue and Forecast, by Product (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Product (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Product (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.2. Market Revenue and Forecast, by Product (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Product (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Product (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Product (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Product (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.2. Market Revenue and Forecast, by Product (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Product (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Product (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Product (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Product (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.2. Market Revenue and Forecast, by Product (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Product (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Product (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Product (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Product (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.5.2. Market Revenue and Forecast, by Product (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Product (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.1. Avadel Pharmaceuticals
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Harmony Biosciences (BIOPROJET)
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Jazz Pharmaceuticals PLC
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Ligand Pharmaceuticals Incorporated
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Novartis AG
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Shionogi Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Takeda Pharmaceutical Company
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Teva Pharmaceuticals Industries Ltd
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Axsome Therapeutics Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. XWPharma Ltd.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample